All patients
age >= 55 yr age >= 60 yr age >= 65 yr autoimmune disease corticosteroids: no corticosteroids: yes critical disease invasive ventilation no oxygen needed non invasive oxygen omicron variant BA.1 (B.1.1.529) severe disease solid organ transplant recipients subjects at risk
anti-inflammatoty and immuno-therapy in COVID-19 mild to moderate - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results CAN-COVID, 2020 0.67 [0.30; 1.50]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.61 [0.41; 0.92]
0.62 [0.43 ; 0.90 ] CAN-COVID, 2020, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 2 0% 1,642 moderate not evaluable deathsdetailed results CAN-COVID, 2020 0.67 [0.30; 1.50]
Libster, 2020 0.50 [0.09; 2.71]
LIVE-AIR (Temesgen), 2021 0.70 [0.40; 1.21]
SAVE-MORE, 2021 0.45 [0.20; 0.99]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.61 [0.41; 0.92]
0.61 [0.46 ; 0.81 ] CAN-COVID, 2020, Libster, 2020, LIVE-AIR (Temesgen), 2021, SAVE-MORE, 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 5 0% 2,875 moderate not evaluable deaths (time to event analysis only)detailed results LIVE-AIR (Temesgen), 2021 0.70 [0.40; 1.21]
0.70 [0.40 ; 1.21 ] LIVE-AIR (Temesgen), 2021 1 0% 479 NA not evaluable clinical deteriorationdetailed results Libster, 2020 0.52 [0.29; 0.94]
SAVE-MORE, 2021 0.36 [0.26; 0.50]
0.40 [0.29 ; 0.55 ] Libster, 2020, SAVE-MORE, 2021 2 13% 160 low not evaluable clinical improvementdetailed results CAN-COVID, 2020 1.39 [0.76; 2.54]
1.39 [0.76 ; 2.54 ] CAN-COVID, 2020 1 0% 446 NA not evaluable death or ventilationdetailed results LIVE-AIR (Temesgen), 2021 0.65 [0.43; 0.98]
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.66 [0.46; 0.94]
0.65 [0.50 ; 0.86 ] LIVE-AIR (Temesgen), 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 2 0% 1,197 moderate not evaluable hospital dischargedetailed results Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 1.48 [1.05; 2.09]
1.48 [1.05 ; 2.09 ] Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 1 0% 1,197 NA not evaluable hospitalizationdetailed results Jagannathan, 2020 1.00 [0.14; 7.34]
1.00 [0.14 ; 7.34 ] Jagannathan, 2020 1 0% 120 NA not evaluable mechanical ventilationdetailed results SAVE-MORE, 2021 0.47 [0.03; 7.48]
0.47 [0.03 ; 7.48 ] SAVE-MORE, 2021 1 0% 594 NA not evaluable viral clearance detailed results Jagannathan, 2020 0.81 [0.56; 1.18]
0.81 [0.56 ; 1.18 ] Jagannathan, 2020 1 0% 120 NA not evaluable viral clearance (time to event analysis only)detailed results Jagannathan, 2020 0.81 [0.56; 1.18]
0.81 [0.56 ; 1.18 ] Jagannathan, 2020 1 0% 120 NA not evaluable ICU admissiondetailed results Libster, 2020 0.33 [0.07; 1.58]
0.33 [0.07 ; 1.58 ] Libster, 2020 1 0% 160 NA not evaluable serious adverse eventsdetailed results CAN-COVID, 2020 0.73 [0.45; 1.19]
Jagannathan, 2020 1.00 [0.14; 7.34]
0.75 [0.47 ; 1.19 ] CAN-COVID, 2020, Jagannathan, 2020 2 0% 568 moderate not evaluable adverse eventsdetailed results Jagannathan, 2020 1.33 [0.63; 2.78]
1.33 [0.63 ; 2.78 ] Jagannathan, 2020 1 0% 120 NA not evaluable 0.2 2.0 1.0 relative treatment effect www.metaEvidence.org 2024-09-24 20:16 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 90
- treatments: 546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525
- roots T: 290